Skip to main content
. Author manuscript; available in PMC: 2010 Jan 7.
Published in final edited form as: Vaccine. 2008 Nov 7;27(2):213–222. doi: 10.1016/j.vaccine.2008.10.046

Table 2.

Immunization of mice with a single dose of rWNV-E

Experiment Treatment group Anti-WNV-E IgG
Mean OD ± S.D. (Range)
a Alhydrogel™ alone control 0.02 ± 0.005 (0.01–0.02)
Baculovirus-produced rWNV-E with Alhydrogel™ 5 μg 0.47 ± 0.43 (0.03–1.49)
Baculovirus-produced rWNV-E alone 5 μg 0.02 ± 0.01 (0.01–0.04)
b Alhydrogel™ alone control 0.01 ± 0.002 (0.004–0.01)
Baculovirus-produced rWNV-E with Alhydrogel™ 5 μg 0.56 ± 0.52 (0.05–1.36)
Drosophila-produced rWNV-E with Alhydrogel™ 5 μg 0.46 ± 0.38 (0.06–1.25)
c Alhydrogel™ alone control 0.09 ± 0.08 (0.08–0.10)
Baculovirus-produced rWNV-E with Alhydrogel™ 2.5 μg 0.28 ± 0.20 (0.11–0.55)
Baculovirus-produced rWNV-E with Alhydrogel™ 5 μg 0.35 ± 0.32 (0.09–0.84)
Baculovirus-produced rWNV-E with Alhydrogel™ 10 μg 0.73 ± 0.46 (0.13–1.42)

Serum samples were collected from groups of 10 mice, 2 weeks after immunization. Presence of IgG antibodies against rWNV-E was determined by ELISA at a 1:50 serum dilution.